Novan, Inc.

Although Novartis was the first company to win US Food and Drug Administration approval for a CAR-T cell therapy with Kymriah (tisagenlecleucel) back in 2017, the market has shifted in favor of compet

While stock markets toyed with all-time highs despite the impeachment of the president, over on the West Coast things were less rosy. There was a plethora of announcements to coincide with the first f

Verrica Pharmaceuticals Inc. is in an anticipatory mode, awaiting a 13 July action date for VP-102, its formulation of cantharidin that is in position to become the first approved therapy in the US f

Novan Inc. thinks a deeper look at its first two Phase III trials for its molluscum contagiosum candidate SB206 shows a way toward filing for approval – assuming it receives confirmatory data from a